Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02839265 · ClinicalTrials.gov registry record · Phase 2
FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02839265 is a Phase 2 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 33 participants.
The verdict
NCT02839265, a Phase 2 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
Based on promising data from our laboratory demonstrating synergy between ablative local radiotherapy and FLT3 ligand immunotherapy in murine NSCLC models, investigators are performing a phase II study combining FLT3L immunotherapy and SBRT for patients with advanced NSCLC that has progressed following standard systemic therapy. All patients will receive daily subcutaneous injections of CDX-301 (75 µg/kg) for 5 days, beginning on the first day of SBRT. SBRT will be delivered to a single pulmonary or extrapulmonary lesion. The SBRT regimen will depend on the size and location of the target lesion. The primary endpoint will be progression-free survival at 4 months, defined using immune-related response criteria (irRC).
Interventions
- RADIATION Stereotactic Body Radiotherapy (SBRT)
- DRUG FLT3 Ligand Therapy (CDX-301)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-07 |
| Est. Completion | 2024-11-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02839265
The ClinicalTrials.gov registry entry for NCT02839265 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Stereotactic Body Radiotherapy (SBRT) is the first listed.
NCT02839265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02839265 about?
NCT02839265 is a clinical study titled "FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer". Based on promising data from our laboratory demonstrating synergy between ablative local radiotherapy and FLT3 ligand immunotherapy in murine NSCLC models, investigators are performing a phase II study combining FLT3L immunotherapy and SBRT for patients with advanced NSCLC that has progressed follow...
What is the current status of trial NCT02839265?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2016-07. Estimated completion is 2024-11-22.
What interventions are being tested in trial NCT02839265?
The interventions under investigation include: Stereotactic Body Radiotherapy (SBRT) (RADIATION), FLT3 Ligand Therapy (CDX-301) (DRUG).
Who is sponsoring clinical trial NCT02839265?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.